Generic drugmakers Teva and Glenmark recently became the sixth and seventh drugmakers to resolve criminal charges as a result of the DOJ’s yearslong investigation into generic drug price fixing. The settlement agreement requires both companies to pay hefty fines as well as divest their drug lines for pravastatin, a widely used statin that lowers cholesterol.
Covid-19 may have hampered investigations and led authorities to shift resources to more obvious frauds, attorneys said. But the pandemic also created new targets to investigate, including telemedicine and CARES Act funding.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
In addition to monetary damages and the guilty pleas, the government is seeking to transform the maker of OxyContin into a public benefit company that would fund efforts to curb opioid abuse and give away drugs to prevent overdose deaths.
After an eight-week trial, Philip Esformes was found guilty for his role in a fraud scheme that involved more than $1.3 billion in fraudulent claims to Medicare and Medicaid for services that weren't provided, weren't medically necessary or were procured through the payment of kickbacks.
The indictment alleges that as part of the scheme, which ran from June 2015 to April 2018, the defendants submitted no less than $931 million in fraudulent claims for payment.
eClinicalWorks and some of its employees will pay $155 million to settle claims that the EHR vendor misrepresented the capabilities of its software and paid kickbacks to certain customers in exchange for promoting its product.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
There's been a new development in the Anthem-Cigna merger saga: On Friday, a U.S. appeals court upheld a lower court's earlier decision to block the $54 billion deal.
Mylan settled with the U.S. Department of Justice to head off potential Medicaid liability claims by federal and state governments.
The U.S. Deparment of Justice is requesting more information from McKesson and Change Healthcare before signing off on the two companies' plans to combine health IT operations into a new, $3.4 billion business.
Aetna had denied any link between the ACA exit and the antitrust lawsuit, but a letter that surfaced this week from Chairman and CEO Mark Bertolini to the Justice Department shows otherwise.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
The investigation into potential fraud could put the brakes on the planned multibillion-dollar acquisition of Alere by Abbott Laboratories.
It's the largest single criminal healthcare fraud case the Justice Department has ever brought against individuals.
The companies disagreed, though some more strongly than others. All four have vowed to defend their planned mergers in court.
Also, a replacement brought in for striking nurses at Allina Health has gone home, opioid use soars and Kentucky's governor outlines his Medicaid rollback plan.
Last week's news that mega-health insurer Anthem has agreed to acquire fellow mega-health insurer Cigna for $48.4 billion has created quite a stir, especially since two more giants, Aetna and Humana had announced just three weeks earlier that they would merge for $37 billion.